-
Real-world experience in treatment of patients with non-small-cell lung cancer with BRAF or cMET exon 14 skipping mutations [Elektronski vir]Janžič, Urška, onkologinja ...BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with ... advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83).Vir: International journal of molecular sciences [Elektronski vir]. - ISSN 1422-0067 (Vol. 24, iss. 16, [article no.] 12840, [in press] 2023, str. 1-14)Vrsta gradiva - e-članek ; neleposlovje za odrasleLeto - 2023Jezik - angleškiCOBISS.SI-ID - 162782979
Avtor
Janžič, Urška, onkologinja |
Shalata, Walid |
Szymczak, Katarzyna |
Dziadziuszko, Rafal |
Jakopović, Marko |
Mountzios, Giannis, 1974- |
Płużański, Adam |
Araújo, António, zdravnik |
Charpidou, Andriani |
Agbarya, Abed
Teme
Medical oncology |
Medicinska onkologija |
nedrobnocelični pljučni rak |
mutacija BRAF V600 |
podatki iz resničnega življenja |
tarčna terapija |
zdravljenje prvega reda |
non-small-cell lung cancer |
BRAF V600 mutation |
cMET exon 14 skipping mutation |
real-world data |
targeted therapy |
first-line therapy
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Janžič, Urška, onkologinja | 51382 |
Shalata, Walid | ![]() |
Szymczak, Katarzyna | ![]() |
Dziadziuszko, Rafal | ![]() |
Jakopović, Marko | ![]() |
Mountzios, Giannis, 1974- | ![]() |
Płużański, Adam | ![]() |
Araújo, António, zdravnik | ![]() |
Charpidou, Andriani | ![]() |
Agbarya, Abed | ![]() |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.